Egalet (EGLT) Misses Q1 EPS by 73c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Egalet (EGLT) Announces Coverage of SPRIX Nasal Spray and ARYMO ER by National Pharmacy Benefit Manager
May 7, 2018 6:09 AM EDTEgalet Corporation (NASDAQ: EGLT) today announced that a national pharmacy benefit manager (PBM) covering 3.5 million member lives has placed SPRIX (ketorolac tromethamine) Nasal Spray in a tier 2 preferred position and ARYMO ER (morphine sulfate) extended-release (ER) tablets for oral use only CII in a tier 3 unrestricted position effective immediately.
"The coverage of SPRIX and AYRMO ER by this national PBM is an important development given our strategy to expand payer coverage of our products," said Patrick Shea, chief commercial officer of Egalet. "With this national PBM and the regional plans recently covering... More
